Table 1A

Variant caller parameters file for variant calling plug in 5.0 tissue adapted

(A) Patients and samples characteristics in relation to SiRe mutational status results
Patients (n=322)	Clinical characteristics n	EGFR n	KRAS n	NRAS n	BRAF n	WT n	Inadequate n
Gender	Male (n=207)*	14†	63†	1	9	98	23
Gender	Female (n=115)‡	36§	29	0	5	41	5
Age	<60 (n=80)	10¶	25¶	0	4	38	3
Age	≥60 (n=242)*^‡	40**	67††	1	10	101	25
Sample type	Cytology (n=180)	30§	46¶	1	8	79	16
Sample type	Histology (n=142)*^‡	20†	46††	0	6	60	12
Site	Primary (n=235)*	36§	75†	1	11	92	21
Site	Metastasis (n=87)‡	14†	17	0	3	47	7
Diagnosis	ADC (n=181)*	32‡‡	49†	1	10	77	13
	Favour ADC (n=101)‡	15‡‡	36	0	3	39	9
	NEC (n=4)	1	0	0	0	3	0
	NOS (n=30)	2	7	0	1	14	6
	SqCC (n=6)	0	0	0	0	6	0
%NC	5–25 (n=98)	13 ††	26	0	1	44	14
	26–50 (n=103)‡	15¶	34††	0	5	41	9
	>50 (n=121)*	22§	32¶	1	8	54	5

*One patient harbouring G12S (KRAS) and D594G (BRAF).
†Three patients harbouring two mutations.
‡One patient harbouring ELREA (EGFR) and Q61R (KRAS).
§Five patients harbouring two mutations.
¶One patient harbouring two mutations.
**Seven patients harbouring two mutations.
††Two patients harbouring two mutations.
‡‡Four patients harbouring two mutations.
ADC, adenocarcinoma; NC, neoplastic cell percentage; %NC, neoplastic cell percentage; NEC, neuroendocrine carcinoma; NOS, not otherwise specified; SqCC, squamous cell carcinoma; WT, wild type.